Detailseite
Projekt Druckansicht

Bekämpfung von Cisplatin-resistenten Tumoren unter Verwendung von responsiven Pt(IV)/Ru(II) Bimetallpolymeren

Antragsteller Professor Dr. Hans-Jürgen Butt, seit 12/2018
Fachliche Zuordnung Präparative und Physikalische Chemie von Polymeren
Förderung Förderung von 2018 bis 2021
Projektkennung Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 392048923
 

Zusammenfassung der Projektergebnisse

Drug resistance is a major problem in cancer treatment. In this project, we designed a dual-responsive Pt(IV)/Ru(II) bimetallic polymer (PolyPt/Ru) to treat cisplatin-resistant tumors. We demonstrated its potential application in a patient-derived xenograft (PDX) model. PolyPt/Ru is an amphiphilic ABA-type triblock copolymer. The hydrophilic A blocks consist of biocompatible poly(ethylene glycol) (PEG). The hydrophobic B block contains reduction-responsive Pt(IV) and red-light-responsive Ru(II) moieties. PolyPt/Ru self-assembles into nanoparticles that are efficiently taken up by cisplatinresistant cancer cells. Irradiation of cancer cells containing PolyPt/Ru nanoparticles with red light generates 1O2, induces polymer degradation, and triggers the release of the Ru(II) anticancer agent. Meanwhile, the anticancer drug, cisplatin, is released in the intracellular environment via reduction of the Pt(IV) moieties. The released Ru(II) anticancer agent, cisplatin, the generated 1O2 have different anticancer mechanisms. Their synergistic effects inhibit the growth of drug-resistant cancer cells. Furthermore, PolyPt/Ru nanoparticles inhibited tumor growth in a PDX mouse model because they circulate in the blood stream, accumulate at tumor sites, exhibit good biocompatibility, and does not cause side effects. Our results demonstrate that the development of stimuli-responsive multi-metallic polymers provides a new strategy to overcome drug resistance.

Projektbezogene Publikationen (Auswahl)

 
 

Zusatzinformationen

Textvergrößerung und Kontrastanpassung